The U.S. Food and Drug Administration deferred a highly anticipated decision on whether to approve Sarepta Therapeutics Inc's muscle-wasting disorder drug, a month after an advisory panel determined that the treatment was not effective.
The U.S. Food and Drug Administration deferred a highly anticipated decision on whether to approve Sarepta Therapeutics Inc's muscle-wasting disorder drug, a month after an advisory panel determined that the treatment was not effective.
Using data from the Centers for Medicare & Medicaid Services, researchers examined trends in the number of beneficiaries switching between Medicare and Medicare Advantage plans from 2014 to 2020.
Using data from the Centers for Medicare & Medicaid Services, researchers examined trends in the number of beneficiaries switching between Medicare and Medicare Advantage plans from 2014 to 2020.
Patients with exacerbations of chronic obstructive pulmonary disease (COPD) may be experiencing instability or worsening of their disease. Worldwide, COPD is the leading cause of disability and death, and exacerbations have been associated...
Patients with exacerbations of chronic obstructive pulmonary disease (COPD) may be experiencing instability or worsening of their disease. Worldwide, COPD is the leading cause of disability and death, and exacerbations have been associated...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
David Sand, MD, MBA, chief medical officer at ZeOmega, discusses the challenges of prior authorization, emphasizing the need for transparency, evidence-based standards, collaboration between payers and providers, and the potential for...
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Richard Lipton, MD, provides insights on the American Headache Society’s position statement update on calcitonin gene-related peptide (CGRP)-targeting therapies as a first-line option for the prevention of migraine.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Learn about research developments in 1L therapy for NSCLC patients with EGFR mutations and how outcomes may impact coverage and reimbursement decisions for insurers.
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Guest expert Jordan Bazinsky discusses the challenges facing the medical imaging industry, the potential of AI and emerging technologies, the role of advanced imaging solutions in promoting health equity, and the key trends and challenges...
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Discover how health care contact centers can transform into drivers of value-based care through AI, automation, upskilling agents, and rethinking workflows and metrics to improve patient outcomes and population health.
Lucille Accetta, PharmD, MBA, MSPH, Senior Vice President of CVS Specialty Operations
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Key stakeholders in the health care industry gathered to discuss prevalent topics at this year's Asembia annual summit. Medication adherence emerged as one of the most talked-about issues. In a session led by Lucille Accetta, PharmD, MBA,...
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.
Learn about the impacts of the Inflation Reduction Act on payers and patients, highlighting the changes in Medicare benefits and drug coverage coming in 2025 and 2026.